A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor

被引：15
|
作者：
Leroy, L. [1 ]
Lafarge, X. [2 ]
Blouin, L. [2 ]
Bijou, F. [3 ]
Durrieu, F. [4 ]
Olivier, E. [5 ]
Le Moulec, S. [1 ]
机构：
[1] Bergonie Inst, Dept Med Oncol, Bordeaux, France
[2] EFS, INSERM, Unit 1035, Bordeaux, France
[3] Bergonie Inst, Dept Med Hematol, Bordeaux, France
[4] Bergonie Inst, Dept Biol Hematol, Bordeaux, France
[5] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷 / 02期
关键词：
IPILIMUMAB-INDUCED THROMBOCYTOPENIA;
D O I：
10.1093/annonc/mdx693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：514 / 515
页数：3
相关论文
共 50 条
  • [31] Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
    Xianjie Jiang
    Jie Wang
    Xiangying Deng
    Fang Xiong
    Junshang Ge
    Bo Xiang
    Xu Wu
    Jian Ma
    Ming Zhou
    Xiaoling Li
    Yong Li
    Guiyuan Li
    Wei Xiong
    Can Guo
    Zhaoyang Zeng
    Molecular Cancer, 18
  • [32] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Laurence P. Diggs
    Eddy C. Hsueh
    Biomarker Research, 5
  • [33] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Diggs, Laurence P.
    Hsueh, Eddy C.
    BIOMARKER RESEARCH, 2017, 5
  • [34] Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
    Jiang, Xianjie
    Wang, Jie
    Deng, Xiangying
    Xiong, Fang
    Ge, Junshang
    Xiang, Bo
    Wu, Xu
    Ma, Jian
    Zhou, Ming
    Li, Xiaoling
    Li, Yong
    Li, Guiyuan
    Xiong, Wei
    Guo, Can
    Zeng, Zhaoyang
    MOLECULAR CANCER, 2019, 18 (1)
  • [35] IMMUNE EVASION MEDIATED BY PD-L1 ON GLIOBLASTOMA DERIVED EXTRACELLULAR VESICLES
    Ricklefs, F. L.
    Speranza, M. C.
    Hayes, J.
    Balaj, L.
    Breakefield, X. O.
    Bronisz, A.
    Carter, B.
    Freeman, G.
    Lawler, S.
    Chiocca, E. A.
    NEURO-ONCOLOGY, 2017, 19 : 50 - 50
  • [36] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
    Tang, Fei
    Zheng, Pan
    CELL AND BIOSCIENCE, 2018, 8
  • [37] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
    Fei Tang
    Pan Zheng
    Cell & Bioscience, 8
  • [38] Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
    Ruiting Li
    Xiaojing Zou
    Huaqing Shu
    You Shang
    Intensive Care Research, 2021, 1 (1-2): : 11 - 15
  • [39] Immune-Mediated Colitis with Novel Immunotherapy: PD1 Inhibitor Associated Gastrointestinal Toxicity
    Gondal, Bilal
    Patel, Parita
    Gallan, Alexander
    Hart, John
    Bissonnette, Marc
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2016, 79 (03) : 379 - 381
  • [40] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
12345